Loading…

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human‐recombinant anti‐interleukin‐17A monoclonal antibody was indicated for psoriasi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2016-09, Vol.43 (9), p.1011-1017
Main Authors: Imafuku, Shinichi, Honma, Masaru, Okubo, Yukari, Komine, Mayumi, Ohtsuki, Mamitaro, Morita, Akimichi, Seko, Noriko, Kawashima, Naoko, Ito, Saori, Shima, Tomohiro, Nakagawa, Hidemi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43
cites cdi_FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43
container_end_page 1017
container_issue 9
container_start_page 1011
container_title Journal of dermatology
container_volume 43
creator Imafuku, Shinichi
Honma, Masaru
Okubo, Yukari
Komine, Mayumi
Ohtsuki, Mamitaro
Morita, Akimichi
Seko, Noriko
Kawashima, Naoko
Ito, Saori
Shima, Tomohiro
Nakagawa, Hidemi
description Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human‐recombinant anti‐interleukin‐17A monoclonal antibody was indicated for psoriasis vulgaris and psoriatic arthritis in Japan but is not yet investigated for GPP. In this phase III, open‐label multicenter single arm study, the efficacy and safety of secukinumab as monotherapy or with co‐medication was evaluated in 12 Japanese patients with GPP. All the patients received secukinumab 150 mg s.c. at baseline, week 1, 2, 3 and 4, and then every 4 weeks. Two non‐responders were up‐titrated to 300 mg. Change in GPP severity from baseline was evaluated by clinical global impression (CGI) categorized as “worsened”, “no change”, “minimally improved”, “much improved” or “very much improved”. Treatment success was achieved by 83.3% (n = 10) of patients at week 16 (primary end‐point) with CGI evaluated as “very much improved” (n = 9) and “much improved” (n = 1). Moreover, the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients. The improvements were sustained throughout 52 weeks. Over the 52‐week treatment period, secukinumab was well tolerated with no unexpected safety signals. Nasopharyngitis, urticaria, diabetes mellitus and arthralgia were the frequent adverse events reported. The data from this study shows that secukinumab can become one of the potent treatment options for GPP.
doi_str_mv 10.1111/1346-8138.13306
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827903233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4168075861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEotvCmRuyxIVLWn8kjsOtKtt2VyuQoIKjNetMqLvOB3aiJf0r_Fm83XYPXGAulkbP-2jkN0neMHrK4pwxkclUMaFOmRBUPktmh83zZEaFylOe0eIoOQ7hjlJe5oy-TI64LFmZMTpLfs_r2howE4G2IgFqHCbS1SSgGTe2HRtYE9uSHgaL7RDI1g635Ae26MHZe6xIP4ZhdOBJHzpvIdjwgZyTnKdbxE2UgpvijtS-a0h_CwHJYrEgXY9t6mCNjjSjG6yJcvRkCT20GJnorKZXyYsaXMDXj-9JcnM5v7m4TlefrxYX56vU5EUh0yLnlVAUlMhUlqmyAqwZNyA5zRCUUpwqKoShyKUxwIpKoinLggIra5OJk-T9Xtv77ueIYdCNDQadi6d0Y9BM8aKkggvxHyiTUuSc5RF99xd6140-fscDlZeSSrYTnu0p47sQPNa697YBP2lG9a5hvetT7_rUDw3HxNtH77husDrwT5VGIN8DW-tw-pdPLz_On8TpPmfDgL8OOfAbLQtR5Pr7pyt9-e3667LMvuiV-APZ_b9S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1815960613</pqid></control><display><type>article</type><title>Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Imafuku, Shinichi ; Honma, Masaru ; Okubo, Yukari ; Komine, Mayumi ; Ohtsuki, Mamitaro ; Morita, Akimichi ; Seko, Noriko ; Kawashima, Naoko ; Ito, Saori ; Shima, Tomohiro ; Nakagawa, Hidemi</creator><creatorcontrib>Imafuku, Shinichi ; Honma, Masaru ; Okubo, Yukari ; Komine, Mayumi ; Ohtsuki, Mamitaro ; Morita, Akimichi ; Seko, Noriko ; Kawashima, Naoko ; Ito, Saori ; Shima, Tomohiro ; Nakagawa, Hidemi</creatorcontrib><description>Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human‐recombinant anti‐interleukin‐17A monoclonal antibody was indicated for psoriasis vulgaris and psoriatic arthritis in Japan but is not yet investigated for GPP. In this phase III, open‐label multicenter single arm study, the efficacy and safety of secukinumab as monotherapy or with co‐medication was evaluated in 12 Japanese patients with GPP. All the patients received secukinumab 150 mg s.c. at baseline, week 1, 2, 3 and 4, and then every 4 weeks. Two non‐responders were up‐titrated to 300 mg. Change in GPP severity from baseline was evaluated by clinical global impression (CGI) categorized as “worsened”, “no change”, “minimally improved”, “much improved” or “very much improved”. Treatment success was achieved by 83.3% (n = 10) of patients at week 16 (primary end‐point) with CGI evaluated as “very much improved” (n = 9) and “much improved” (n = 1). Moreover, the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients. The improvements were sustained throughout 52 weeks. Over the 52‐week treatment period, secukinumab was well tolerated with no unexpected safety signals. Nasopharyngitis, urticaria, diabetes mellitus and arthralgia were the frequent adverse events reported. The data from this study shows that secukinumab can become one of the potent treatment options for GPP.</description><identifier>ISSN: 0385-2407</identifier><identifier>EISSN: 1346-8138</identifier><identifier>DOI: 10.1111/1346-8138.13306</identifier><identifier>PMID: 26919410</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Arthralgia - chemically induced ; clinical global impression ; Diabetes Mellitus - chemically induced ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; generalized pustular psoriasis ; Humans ; Interleukin-17 - antagonists &amp; inhibitors ; interleukin-17A ; Japan ; Male ; Middle Aged ; Nasopharyngitis - chemically induced ; Practice Guidelines as Topic ; Prescription drugs ; Psoriasis ; Psoriasis - drug therapy ; Psoriasis Area and Severity Index ; secukinumab ; Severity of Illness Index ; Treatment Outcome ; Urticaria - chemically induced</subject><ispartof>Journal of dermatology, 2016-09, Vol.43 (9), p.1011-1017</ispartof><rights>2016 Japanese Dermatological Association</rights><rights>2016 Japanese Dermatological Association.</rights><rights>Copyright © 2016 Japanese Dermatological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43</citedby><cites>FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26919410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Imafuku, Shinichi</creatorcontrib><creatorcontrib>Honma, Masaru</creatorcontrib><creatorcontrib>Okubo, Yukari</creatorcontrib><creatorcontrib>Komine, Mayumi</creatorcontrib><creatorcontrib>Ohtsuki, Mamitaro</creatorcontrib><creatorcontrib>Morita, Akimichi</creatorcontrib><creatorcontrib>Seko, Noriko</creatorcontrib><creatorcontrib>Kawashima, Naoko</creatorcontrib><creatorcontrib>Ito, Saori</creatorcontrib><creatorcontrib>Shima, Tomohiro</creatorcontrib><creatorcontrib>Nakagawa, Hidemi</creatorcontrib><title>Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study</title><title>Journal of dermatology</title><addtitle>J Dermatol</addtitle><description>Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human‐recombinant anti‐interleukin‐17A monoclonal antibody was indicated for psoriasis vulgaris and psoriatic arthritis in Japan but is not yet investigated for GPP. In this phase III, open‐label multicenter single arm study, the efficacy and safety of secukinumab as monotherapy or with co‐medication was evaluated in 12 Japanese patients with GPP. All the patients received secukinumab 150 mg s.c. at baseline, week 1, 2, 3 and 4, and then every 4 weeks. Two non‐responders were up‐titrated to 300 mg. Change in GPP severity from baseline was evaluated by clinical global impression (CGI) categorized as “worsened”, “no change”, “minimally improved”, “much improved” or “very much improved”. Treatment success was achieved by 83.3% (n = 10) of patients at week 16 (primary end‐point) with CGI evaluated as “very much improved” (n = 9) and “much improved” (n = 1). Moreover, the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients. The improvements were sustained throughout 52 weeks. Over the 52‐week treatment period, secukinumab was well tolerated with no unexpected safety signals. Nasopharyngitis, urticaria, diabetes mellitus and arthralgia were the frequent adverse events reported. The data from this study shows that secukinumab can become one of the potent treatment options for GPP.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Arthralgia - chemically induced</subject><subject>clinical global impression</subject><subject>Diabetes Mellitus - chemically induced</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>generalized pustular psoriasis</subject><subject>Humans</subject><subject>Interleukin-17 - antagonists &amp; inhibitors</subject><subject>interleukin-17A</subject><subject>Japan</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasopharyngitis - chemically induced</subject><subject>Practice Guidelines as Topic</subject><subject>Prescription drugs</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis Area and Severity Index</subject><subject>secukinumab</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Urticaria - chemically induced</subject><issn>0385-2407</issn><issn>1346-8138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhiMEotvCmRuyxIVLWn8kjsOtKtt2VyuQoIKjNetMqLvOB3aiJf0r_Fm83XYPXGAulkbP-2jkN0neMHrK4pwxkclUMaFOmRBUPktmh83zZEaFylOe0eIoOQ7hjlJe5oy-TI64LFmZMTpLfs_r2howE4G2IgFqHCbS1SSgGTe2HRtYE9uSHgaL7RDI1g635Ae26MHZe6xIP4ZhdOBJHzpvIdjwgZyTnKdbxE2UgpvijtS-a0h_CwHJYrEgXY9t6mCNjjSjG6yJcvRkCT20GJnorKZXyYsaXMDXj-9JcnM5v7m4TlefrxYX56vU5EUh0yLnlVAUlMhUlqmyAqwZNyA5zRCUUpwqKoShyKUxwIpKoinLggIra5OJk-T9Xtv77ueIYdCNDQadi6d0Y9BM8aKkggvxHyiTUuSc5RF99xd6140-fscDlZeSSrYTnu0p47sQPNa697YBP2lG9a5hvetT7_rUDw3HxNtH77husDrwT5VGIN8DW-tw-pdPLz_On8TpPmfDgL8OOfAbLQtR5Pr7pyt9-e3667LMvuiV-APZ_b9S</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>Imafuku, Shinichi</creator><creator>Honma, Masaru</creator><creator>Okubo, Yukari</creator><creator>Komine, Mayumi</creator><creator>Ohtsuki, Mamitaro</creator><creator>Morita, Akimichi</creator><creator>Seko, Noriko</creator><creator>Kawashima, Naoko</creator><creator>Ito, Saori</creator><creator>Shima, Tomohiro</creator><creator>Nakagawa, Hidemi</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201609</creationdate><title>Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study</title><author>Imafuku, Shinichi ; Honma, Masaru ; Okubo, Yukari ; Komine, Mayumi ; Ohtsuki, Mamitaro ; Morita, Akimichi ; Seko, Noriko ; Kawashima, Naoko ; Ito, Saori ; Shima, Tomohiro ; Nakagawa, Hidemi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Arthralgia - chemically induced</topic><topic>clinical global impression</topic><topic>Diabetes Mellitus - chemically induced</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>generalized pustular psoriasis</topic><topic>Humans</topic><topic>Interleukin-17 - antagonists &amp; inhibitors</topic><topic>interleukin-17A</topic><topic>Japan</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasopharyngitis - chemically induced</topic><topic>Practice Guidelines as Topic</topic><topic>Prescription drugs</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis Area and Severity Index</topic><topic>secukinumab</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Urticaria - chemically induced</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Imafuku, Shinichi</creatorcontrib><creatorcontrib>Honma, Masaru</creatorcontrib><creatorcontrib>Okubo, Yukari</creatorcontrib><creatorcontrib>Komine, Mayumi</creatorcontrib><creatorcontrib>Ohtsuki, Mamitaro</creatorcontrib><creatorcontrib>Morita, Akimichi</creatorcontrib><creatorcontrib>Seko, Noriko</creatorcontrib><creatorcontrib>Kawashima, Naoko</creatorcontrib><creatorcontrib>Ito, Saori</creatorcontrib><creatorcontrib>Shima, Tomohiro</creatorcontrib><creatorcontrib>Nakagawa, Hidemi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Imafuku, Shinichi</au><au>Honma, Masaru</au><au>Okubo, Yukari</au><au>Komine, Mayumi</au><au>Ohtsuki, Mamitaro</au><au>Morita, Akimichi</au><au>Seko, Noriko</au><au>Kawashima, Naoko</au><au>Ito, Saori</au><au>Shima, Tomohiro</au><au>Nakagawa, Hidemi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study</atitle><jtitle>Journal of dermatology</jtitle><addtitle>J Dermatol</addtitle><date>2016-09</date><risdate>2016</risdate><volume>43</volume><issue>9</issue><spage>1011</spage><epage>1017</epage><pages>1011-1017</pages><issn>0385-2407</issn><eissn>1346-8138</eissn><abstract>Generalized pustular psoriasis (GPP) is a severe inflammatory skin disease characterized by the presence of sterile pustules covering almost the entire body and systemic symptoms such as fever. Secukinumab, a fully human‐recombinant anti‐interleukin‐17A monoclonal antibody was indicated for psoriasis vulgaris and psoriatic arthritis in Japan but is not yet investigated for GPP. In this phase III, open‐label multicenter single arm study, the efficacy and safety of secukinumab as monotherapy or with co‐medication was evaluated in 12 Japanese patients with GPP. All the patients received secukinumab 150 mg s.c. at baseline, week 1, 2, 3 and 4, and then every 4 weeks. Two non‐responders were up‐titrated to 300 mg. Change in GPP severity from baseline was evaluated by clinical global impression (CGI) categorized as “worsened”, “no change”, “minimally improved”, “much improved” or “very much improved”. Treatment success was achieved by 83.3% (n = 10) of patients at week 16 (primary end‐point) with CGI evaluated as “very much improved” (n = 9) and “much improved” (n = 1). Moreover, the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients. The improvements were sustained throughout 52 weeks. Over the 52‐week treatment period, secukinumab was well tolerated with no unexpected safety signals. Nasopharyngitis, urticaria, diabetes mellitus and arthralgia were the frequent adverse events reported. The data from this study shows that secukinumab can become one of the potent treatment options for GPP.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26919410</pmid><doi>10.1111/1346-8138.13306</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0385-2407
ispartof Journal of dermatology, 2016-09, Vol.43 (9), p.1011-1017
issn 0385-2407
1346-8138
language eng
recordid cdi_proquest_miscellaneous_1827903233
source Wiley-Blackwell Read & Publish Collection
subjects Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Arthralgia - chemically induced
clinical global impression
Diabetes Mellitus - chemically induced
Dose-Response Relationship, Drug
Double-Blind Method
Female
generalized pustular psoriasis
Humans
Interleukin-17 - antagonists & inhibitors
interleukin-17A
Japan
Male
Middle Aged
Nasopharyngitis - chemically induced
Practice Guidelines as Topic
Prescription drugs
Psoriasis
Psoriasis - drug therapy
Psoriasis Area and Severity Index
secukinumab
Severity of Illness Index
Treatment Outcome
Urticaria - chemically induced
title Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A19%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20secukinumab%20in%20patients%20with%20generalized%20pustular%20psoriasis:%20A%2052-week%20analysis%20from%20phase%20III%20open-label%20multicenter%20Japanese%20study&rft.jtitle=Journal%20of%20dermatology&rft.au=Imafuku,%20Shinichi&rft.date=2016-09&rft.volume=43&rft.issue=9&rft.spage=1011&rft.epage=1017&rft.pages=1011-1017&rft.issn=0385-2407&rft.eissn=1346-8138&rft_id=info:doi/10.1111/1346-8138.13306&rft_dat=%3Cproquest_cross%3E4168075861%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5776-752d380a83484489daef12ca6204ea888208033c0e26cca17d6ec9970a19fc43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1815960613&rft_id=info:pmid/26919410&rfr_iscdi=true